Endo Pharmaceuticals to Pay Nearly $200 Million for False Marketing
From Ring of Fire:
“Failing to adhere to the safety and marketing standards put in place by the FDA can cause enormous risk to patients,” says Christopher Paulos, an attorney with the Levin, Papantonio law firm who practices in the areas of product liability, bad drug and False Claims Act litigation. “But time after time companies continue to put their own gains, their profits, before the safety and well-being of patients and consumers.”
Last Friday, the Department of Justice announced that the pharmaceutical health companies Endo Pharmaceuticals and Endo Health Solutions would pay $192.7 million in order to resolve both criminal and civil charges over the companies’ marketing of Lidoderm.
Lidoderm is a topical patch used to relieve pain. Once applied it will cause numbing or loss of feeling in the area of the body to which it is applied. The product is often used with surgery and in treatment of emergency heart rhythm problems. The product was only approved by the FDA for the relief of post-herpetic neuralgia (PHN).
You can read the full article here at Ring of Fire.
